[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584874":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":42,"studyPopulation":34,"armGroups":43,"interventions":50,"overallOfficials":34,"centralContacts":56,"locations":65,"responsibleParty":84,"collaborators":34,"id":86,"slug":34,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":34,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":68,"whyStopped":34,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":34},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Dose-Limiting Toxicity (DLT)","The number of participants experiencing dose-limiting toxicities (DLT) during the dose-escalation period of the study.","21 days",{"measure":14,"description":15,"timeFrame":16},"Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEs","The incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including abnormalities in laboratory values and vital signs.","Up to 3 years",{"measure":18,"description":19,"timeFrame":16},"Overall Response Rate (ORR)","Overall response rate assessed per RECIST v1.1 criteria.",[21,25,28,31],{"measure":22,"description":23,"timeFrame":24},"Maximum Observed Blood Concentration (Cmax) of JYP0015","Maximum plasma concentration (Cmax) of JYP0015 following administration.","Up to 16 weeks",{"measure":26,"description":27,"timeFrame":24},"Time to Reach Maximum Blood Concentration (Tmax) of JYP0015","Time to reach maximum plasma concentration (Tmax) of JYP0015 following administration.",{"measure":29,"description":30,"timeFrame":16},"Duration of Response (DOR)","Duration of response as assessed by RECIST v1.1.",{"measure":32,"description":33,"timeFrame":16},"Time to Response (TTR)","Time to response as assessed by RECIST v1.1.",null,{"allocation":36,"interventionModel":37,"interventionModelDescription":38,"primaryPurpose":39,"observationalModel":34,"timePerspective":34,"maskingInfo":40},"NA","SINGLE_GROUP","None (Open Label)","TREATMENT",{"masking":41,"maskingDescription":34,"whoMasked":34},"NONE","This is a Phase 1\u002F2, multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of JYP0015 in adult patients with advanced solid tumors harboring specific RAS mutations.\n\nThe study consists of two parts:\n\n* Phase 1 (dose escalation) - Evaluates the safety, tolerability, and pharmacokinetic profile of JYP0015 monotherapy, preliminarily assesses efficacy, and determines the recommended dose (RD) for further evaluation.\n* Phase 2 (indication expansion) - Explores the therapeutic potential of JYP0015 monotherapy at the RD across four predefined cohorts:\n\n  1. Pancreatic ductal adenocarcinoma (PDAC)\n  2. Non-small cell lung cancer (NSCLC)\n  3. Colorectal cancer (CRC)\n  4. Other advanced solid tumors Phase 2 will assess both efficacy and safety within these cohorts.\n\nJYP0015 is a potent, orally bioavailable pan-RAS inhibitor that selectively targets the active (ON) form of wild-type and mutant RAS across all three isoforms-HRAS, NRAS, and KRAS.",[44],{"label":45,"type":46,"description":47,"interventionNames":48},"JYP0015 in RAS-Mutant Solid Tumors","EXPERIMENTAL","This arm includes participants with histologically or pathologically confirmed advanced solid tumors harboring RAS mutations, identified via molecular testing. RAS mutations are defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, 61, 117, or 146 (e.g., G12, G13, Q61, K117, or A146). Participants will receive JYP0015 as an oral tablet.",[49],"Drug: JYP0015",[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":34},"DRUG","JYP0015","JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.",[45],[57,63],{"name":58,"role":59,"phone":60,"phoneExt":61,"email":62},"Ling Shen, M.D.","CONTACT","01088121122","+86","linshenpku@163.com",{"name":64,"role":59,"phone":34,"phoneExt":34,"email":34},"Xiao",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":75,"coordinates":76},"Point",[77,78],116.39723,39.9075,{"lat":78,"lon":77},[81],{"name":82,"role":59,"phone":83,"phoneExt":61,"email":62},"Shen Lin, M.D.","010-88196861",{"type":85,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100584874",false,"NCT06895031","Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Multi-center, Open-label, Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation","STAR","Inclusion Criteria:\n\n1. Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.\n2. Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment\n3. Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1\n4. Adequate organ function\n\nExclusion Criteria:\n\n1. Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.\n2. Gastrointestinal (GI) disorders that may interfere with drug administration\u002Fabsorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)\n3. Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \\\u003C50%.\n4. Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.","ALL","18 Years","75 Years",{"count":97,"type":98},210,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.",[104,105,106,107],"Solid Tumor","Pancreatic Ductal Adenocarcinoma (PDAC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)",[109,110,111],"PDAC","NSCLC","CRC","2026-03-04",{"date":114,"type":115},"2026-03-06","ACTUAL",{"date":117,"type":115},"2025-03-31",{"date":119,"type":98},"2026-12-31",{"name":5,"class":6},1]